OTTAWA, ON, Aug. 5, 2025 /CNW/ -
Original Notice
At a glance
Do not consume, use, sell, serve or distribute recalled pistachios and pistachio-containing products. For details on recalled...
HARLEM, N.Y., Aug. 5, 2025 /PRNewswire/ -- Legionnaires' disease lawyer Jory Lange and prominent Manhattan attorney Scott Harford have been retained to investigate an...
Dr Jill's MDLifespan Mold Protocol is the First Clinically Proven Therapeutic Plasma Exchange Detox to Remove up to 90% of Mold Toxins
DENVER, Aug. 4,...
First-ever cross-border Green Medical Pass
Integrating resources from both regions for efficient access to healthcare services
HONG KONG, Aug. 4, 2025 /PRNewswire/ -- AXA Hong...
WASHINGTON, Aug. 1, 2025 /PRNewswire/ -- Today, the National Safety Council issued the following statement in response to the U.S. Senate Appropriations Committee's passage of...
MECHANICSBURG, Pa., July 31, 2025 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its...
Net income available to common stockholders of $5.5 million and $48.0 million for the three and six months ended June 30, 2025, respectively, or $0.09 and $0.79 per diluted share, respectively.
New York City, NY, July 29, 2025 (GLOBE NEWSWIRE) --
In 2025, PhenQ is setting a new standard for belly fat burners with its research-driven, natural solution, providing powerful, long-lasting support for a slimmer, healthier stomach without injections or unwanted side effects, and supporting a healthier, more sustainable lifestyle.
Company to Honor Leader's Legacy at CONNECT 2025 Conference Next Week
BLOOMINGTON, Minn., July 28, 2025 /PRNewswire/ -- Avionté, a leader in enterprise staffing and...
SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.
Leader In Delivering Home-Based Health and Care Services Partners with Laboratory Known for Quality, Reliability and Innovation
NASHVILLE, Tenn., July 23, 2025 /PRNewswire/ -- Matrix Medical...
Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the hidden dangers of cholesterol
Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the hidden dangers of cholesterol
NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”2